Form 4 for PMVP PMV Pharmaceuticals, Inc.
Accepted 2022-04-21 00:00:00 ET · period of report 2022-04-20 · accession 0001209191-22-025171 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-04-21 | 2022-04-20 | PMVP | Kung Winston | COO, CFO | M - OptEx | $3.22 | +4,000 | 10.6K | +61% | +$12.9K |
| D | 2022-04-21 | 2022-04-20 | PMVP | Kung Winston | COO, CFO | M - OptEx | $0.00 | -4,000 | 210.0K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-20 | M | A | 4,000 | $3.22 | 10,600 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2022-04-20 | M | D | 4,000 | $0.00 | 210,034 | D | $3.22 · — to 2028-02-21 | 4,000 Common Stock | (F1) The option is subject to an early exercise provision and is immediately exercisable. The underlying shares vest in accordance with the terms of the option grant. |